Evidence map›Paper›PMID 32975058›Full record

ArticleYonsei medical journal2020

Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies.

Min Chul Choi, Yong Wha Moon, Sang Geun Jung, Hyun Park, Won Duk Joo, Seung Hun Song, Chan Lee, Gwangil Kim, Kyoung Ah Kim

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Yonsei medical journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Min Chul Choi *Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA University, Seongnam, Korea. oursk79@cha.ac.kr.ORCID https://orcid.org/0000-0003-4509-6731
Yong Wha Moon *Hematology and Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.ORCID https://orcid.org/0000-0002-7943-974X
Sang Geun JungComprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA University, Seongnam, Korea.ORCID https://orcid.org/0000-0002-0635-6994
Hyun ParkComprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA University, Seongnam, Korea.ORCID https://orcid.org/0000-0002-7825-9165
Won Duk JooComprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA University, Seongnam, Korea. wdjoo@cha.ac.kr.ORCID https://orcid.org/0000-0003-4637-6946
Seung Hun SongComprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA University, Seongnam, Korea.ORCID https://orcid.org/0000-0002-9192-8984
Chan LeeComprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA University, Seongnam, Korea.ORCID https://orcid.org/0000-0003-1654-4398
Gwangil KimDepartment of Pathology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.ORCID https://orcid.org/0000-0002-4867-9003
Kyoung Ah KimDepartment of Radiology, CHA Bundang Medical Center, CHA University, Seongnam, Korea.ORCID https://orcid.org/0000-0003-4997-4829
CHA University Bundang Medical Center · KR

Funding

Korea Health Industry Development Institute HI16C1559
6 · The paper itself

Abstract

purposeWe evaluated the efficacy and safety of pembrolizumab in patients with recurrent gynecologic cancers in real-world practice. MATERIALS AND

methodsWe conducted a retrospective, single-institution study of patients with recurrent gynecologic malignancies treated with pembrolizumab. The primary endpoints were the objective response rate (ORR) and safety.

resultsThirty-one patients treated with pembrolizumab were included. The primary disease sites were the uterine cervix (n=18), ovaries (n=8), and uterine corpus (n=5). Fifteen of the 31 patients (48%) had an Eastern Cooperative Oncology Group performance status of ≥2. The median number of prior chemotherapy lines was 2 (range, 1-6), and 14 of 31 patients (45%) had received ≥ 3 prior lines of chemotherapy. The overall ORR was 22.6%: specifically, 22.3% (4 of 18 patients), 12.5% (1 of 8 patients), and 40% (2 of 5 patients) for cervical, ovarian, and endometrial cancers, respectively. During a median follow-up of 4.7 months (range, 0.2-35.3), the median time to response was 1.9 months (range, 1.4-5.7). The median duration of response was not reached (range, 8.8-not reached). The median progression-free survival was 2.5 months (95% confidence interval, 1.7-not reached). Adverse events occurred in 20 patients (64.5%), and only 3 (9.7%) were grade ≥3. There was one case of suspicious treatment-related mortality, apart from which most adverse events were manageable.

conclusionIn real-world practice, pembrolizumab was feasible and effective in heavily treated recurrent gynecologic cancer patients with poor performance status who may not be eligible for enrollment in clinical trials.

Indexed as

AdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalEndometrial NeoplasmsFemaleGenital Neoplasms, FemaleHumansMiddle AgedNeoplasm Recurrence, LocalProgression-Free SurvivalRetrospective StudiesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalpembrolizumabGynecologic neoplasmspembrolizumabrecurrence

Identifiers

PMID32975058
PMCPMC7515778
OpenAlexW3087780810

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.